학술논문

Development of apratoxin S10 (Apra S10) as an anti-pancreatic cancer agent and its preliminary evaluation in an orthotopic patient-derived xenograft (PDX) model.
Document Type
Article
Source
Investigational New Drugs; Apr2019, Vol. 37 Issue 2, p364-374, 11p
Subject
ANTINEOPLASTIC agents
BIOLOGICAL transport
CELL physiology
CONNECTIVE tissue cells
CYTOKINES
DRUG resistance in cancer cells
MOLECULAR structure
GENETIC mutation
PANCREATIC tumors
TRANSFERASES
XENOGRAFTS
DRUG development
INVESTIGATIONAL drugs
Language
ISSN
01676997
Abstract
Copyright of Investigational New Drugs is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)